suPAR - Ansatte ved Biomedicinsk Institut

suPAR: A New Biomarker for Cardiovascular Disease?

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

suPAR : A New Biomarker for Cardiovascular Disease? / Hodges, Gethin W; Bang, Casper N; Wachtell, Kristian; Eugen-Olsen, Jesper; Jeppesen, Jørgen L.

I: Canadian Journal of Cardiology, Bind 31, Nr. 10, 10.2015, s. 1293-302.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Hodges, GW, Bang, CN, Wachtell, K, Eugen-Olsen, J & Jeppesen, JL 2015, 'suPAR: A New Biomarker for Cardiovascular Disease?', Canadian Journal of Cardiology, bind 31, nr. 10, s. 1293-302. https://doi.org/10.1016/j.cjca.2015.03.023

APA

Hodges, G. W., Bang, C. N., Wachtell, K., Eugen-Olsen, J., & Jeppesen, J. L. (2015). suPAR: A New Biomarker for Cardiovascular Disease? Canadian Journal of Cardiology, 31(10), 1293-302. https://doi.org/10.1016/j.cjca.2015.03.023

Vancouver

Hodges GW, Bang CN, Wachtell K, Eugen-Olsen J, Jeppesen JL. suPAR: A New Biomarker for Cardiovascular Disease? Canadian Journal of Cardiology. 2015 okt.;31(10):1293-302. https://doi.org/10.1016/j.cjca.2015.03.023

Author

Hodges, Gethin W ; Bang, Casper N ; Wachtell, Kristian ; Eugen-Olsen, Jesper ; Jeppesen, Jørgen L. / suPAR : A New Biomarker for Cardiovascular Disease?. I: Canadian Journal of Cardiology. 2015 ; Bind 31, Nr. 10. s. 1293-302.

Bibtex

@article{e31b9dd32c6341bc9160bacb66b3b864,

title = "suPAR: A New Biomarker for Cardiovascular Disease?",

abstract = "The fundamental role of inflammation in cardiovascular disease (CVD) has prompted interest in numerous biomarkers that detect subclinical levels of inflammation. Soluble urokinase plasminogen activator receptor (suPAR) is a novel biomarker that correlates significantly with cardiovascular events and outperforms traditional markers of inflammation such as C-reactive protein (CRP) in prognosticating a range of CVDs. Furthermore, of particular interest is the suggestion that suPAR reflects a pathophysiological pathway more closely linked with subclinical organ damage than CRP. We provide the first comprehensive review of suPAR in CVD and explore its function and usefulness in predicting cardiovascular events.",

keywords = "Biomarkers, Cardiovascular Diseases, Humans, Inflammation, Predictive Value of Tests, Prognosis, Receptors, Urokinase Plasminogen Activator",

author = "Hodges, {Gethin W} and Bang, {Casper N} and Kristian Wachtell and Jesper Eugen-Olsen and Jeppesen, {J{\o}rgen L}",

year = "2015",

month = oct,

doi = "10.1016/j.cjca.2015.03.023",

language = "English",

volume = "31",

pages = "1293--302",

journal = "Canadian Journal of Cardiology",

issn = "0828-282X",

publisher = "Elsevier",

number = "10",

}

RIS

TY - JOUR

T1 - suPAR

T2 - A New Biomarker for Cardiovascular Disease?

AU - Hodges, Gethin W

AU - Bang, Casper N

AU - Wachtell, Kristian

AU - Eugen-Olsen, Jesper

AU - Jeppesen, Jørgen L

PY - 2015/10

Y1 - 2015/10

N2 - The fundamental role of inflammation in cardiovascular disease (CVD) has prompted interest in numerous biomarkers that detect subclinical levels of inflammation. Soluble urokinase plasminogen activator receptor (suPAR) is a novel biomarker that correlates significantly with cardiovascular events and outperforms traditional markers of inflammation such as C-reactive protein (CRP) in prognosticating a range of CVDs. Furthermore, of particular interest is the suggestion that suPAR reflects a pathophysiological pathway more closely linked with subclinical organ damage than CRP. We provide the first comprehensive review of suPAR in CVD and explore its function and usefulness in predicting cardiovascular events.

AB - The fundamental role of inflammation in cardiovascular disease (CVD) has prompted interest in numerous biomarkers that detect subclinical levels of inflammation. Soluble urokinase plasminogen activator receptor (suPAR) is a novel biomarker that correlates significantly with cardiovascular events and outperforms traditional markers of inflammation such as C-reactive protein (CRP) in prognosticating a range of CVDs. Furthermore, of particular interest is the suggestion that suPAR reflects a pathophysiological pathway more closely linked with subclinical organ damage than CRP. We provide the first comprehensive review of suPAR in CVD and explore its function and usefulness in predicting cardiovascular events.

KW - Biomarkers

KW - Cardiovascular Diseases

KW - Humans

KW - Inflammation

KW - Predictive Value of Tests

KW - Prognosis

KW - Receptors, Urokinase Plasminogen Activator

U2 - 10.1016/j.cjca.2015.03.023

DO - 10.1016/j.cjca.2015.03.023

M3 - Review

C2 - 26118447

VL - 31

SP - 1293

EP - 1302

JO - Canadian Journal of Cardiology

JF - Canadian Journal of Cardiology

SN - 0828-282X

IS - 10

ER -

ID: 162248948